{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:42Z","timestamp":1790633382114,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"DOI":"10.1093\/jac\/dkw557","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T12:05:39Z","timestamp":1480680339000},"page":"dkw557","source":"Crossref","is-referenced-by-count":10,"title":["Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)"],"prefix":"10.1093","author":[{"given":"Simona","family":"Di Giambenedetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Latini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"D\u2019Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Chinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Grima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Mondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Colafigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Atlas-M Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,15]]},"reference":[{"key":"2017011617251162000_dkw557v1.1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000233310.90484.16"},{"key":"2017011617251162000_dkw557v1.2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0325-8"},{"key":"2017011617251162000_dkw557v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61170-3"},{"key":"2017011617251162000_dkw557v1.4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QAI.0000000000000904","article-title":"Switch to ritonavir-boosted atazanavir plus raltegravir in virologically suppressed patients with HIV-1 infection: a randomized pilot study","volume":"71","author":"Van Lunzen","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2017011617251162000_dkw557v1.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022003"},{"key":"2017011617251162000_dkw557v1.6","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12348"},{"key":"2017011617251162000_dkw557v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00176-9"},{"key":"2017011617251162000_dkw557v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70736-4"},{"key":"2017011617251162000_dkw557v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt007"},{"key":"2017011617251162000_dkw557v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku402"},{"key":"2017011617251162000_dkw557v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv037"},{"key":"2017011617251162000_dkw557v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00097-3"},{"key":"2017011617251162000_dkw557v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00096-1"},{"key":"2017011617251162000_dkw557v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ed1932"},{"key":"2017011617251162000_dkw557v1.15","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"2017011617251162000_dkw557v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp132"},{"key":"2017011617251162000_dkw557v1.17","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0, November 2014. http:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf."},{"key":"2017011617251162000_dkw557v1.18","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Last updated July 14, 2016. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"2017011617251162000_dkw557v1.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00785.x"},{"key":"2017011617251162000_dkw557v1.20","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","article-title":"Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study","volume":"3","author":"Mocroft","year":"2016","journal-title":"Lancet HIV"},{"key":"2017011617251162000_dkw557v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000407"},{"key":"2017011617251162000_dkw557v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"2017011617251162000_dkw557v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq464"},{"key":"2017011617251162000_dkw557v1.24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jinf.2016.08.011","article-title":"Simplification to a dual regimen with darunavir\/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients","volume":"73","author":"Fabbiani","year":"2016","journal-title":"J Infect"},{"key":"2017011617251162000_dkw557v1.25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/QAD.0000000000001058","article-title":"Once-daily maraviroc versus tenofovir\/emtricitabine each combined with darunavir\/ritonavir for initial HIV-1 treatment","volume":"30","author":"Stellbrink","year":"2016","journal-title":"AIDS"},{"key":"2017011617251162000_dkw557v1.26","unstructured":"Rossetti B Gagliardini R Meini J . Switch to maraviroc (MVC) + darunavir\/ritonavir (DRV\/r) in virologically suppressed patients with R5-tropic virus is associated with an excess of virological failures: 48 weeks results of the GUSTA study. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, Spain, 2015. Abstract PE7\/14. European AIDS Clinical Society."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:07:52Z","timestamp":1498367272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,15]]},"references-count":26,"alternative-id":["10.1093\/jac\/dkw557"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw557","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,15]]}}}